[Controlled randomized clinical trials of immunomodulators diucifon and sodium nucleinate in children with recurrent suppurative infections].
There were 3 groups of children with recurrent purulent infections, who were entered into randomized clinical studies. Group 1 received sodium nucleinate, group 2 diucifon and group 3 placebo (calcium gluconate). After 6 months a well-defined clinical effect manifested by the lowering of the rate and gravity of exacerbations was recorded in 68% of the patients belonging to groups 1 and 2 and in 39% of group 3 patients, which is much more seldom (p less than 0.05). During immunological studies according to the level I tests, no significant changes in the indicators were recorded either before or after the treatment both among the patients who responded to immunotherapy and among those who did not respond to it. The conclusion is drawn that if indicated clinically, sodium nucleinate of diucifon can be administered in spite of the normal immune status in accordance with the level I tests.
Iartsev
M N
MN
Komel'
G I
GI
Gomes
L A
LA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007223:Infant; D007239:Infections / Q000188:drug therapy*; D008297:Male; D009696:Nucleic Acids / Q000627:therapeutic use*; D012331:RNA, Fungal; D012008:Recurrence; D013450:Sulfones / Q000627:therapeutic use*; D013492:Suppuration; D014498:Uracil / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D009696:Nucleic Acids; D012331:RNA, Fungal; D013450:Sulfones; C023367:diucifon; D014498:Uracil; C013683:sodium nucleinate
Kontroliruemye randomizirovannye klinicheskie ispytaniia immunomoduliatorov diutsifona i nukleinata natriia u deteĭ s retsidiviruiushchimi gnoĭnymi infektsiiami.